[go: up one dir, main page]

WO2013011179A3 - Vecteurs recombinants à base du virus ankara modifié (mva) avec délétion dans le gène c6l, utilisés comme vaccins contre le vih/sida et d'autres maladies - Google Patents

Vecteurs recombinants à base du virus ankara modifié (mva) avec délétion dans le gène c6l, utilisés comme vaccins contre le vih/sida et d'autres maladies Download PDF

Info

Publication number
WO2013011179A3
WO2013011179A3 PCT/ES2012/070521 ES2012070521W WO2013011179A3 WO 2013011179 A3 WO2013011179 A3 WO 2013011179A3 ES 2012070521 W ES2012070521 W ES 2012070521W WO 2013011179 A3 WO2013011179 A3 WO 2013011179A3
Authority
WO
WIPO (PCT)
Prior art keywords
mva
virus
aids
diseases
gene
Prior art date
Application number
PCT/ES2012/070521
Other languages
English (en)
Spanish (es)
Other versions
WO2013011179A2 (fr
Inventor
Juan Francisco GARCÍA ARRIAZA
Carmen Elena Gómez Rodríguez
Mariano ESTEBAN RODRÍGUEZ
Original Assignee
Consejo Superior De Investigaciones Científicas (Csic)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior De Investigaciones Científicas (Csic) filed Critical Consejo Superior De Investigaciones Científicas (Csic)
Publication of WO2013011179A2 publication Critical patent/WO2013011179A2/fr
Publication of WO2013011179A3 publication Critical patent/WO2013011179A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention relève du domaine de la biologie moléculaire et de la biotechnologie. Elle concerne plus spécifiquement des virus recombinants à base du virus Ankara modifié (MVA) qui expriment les antigènes gp120 et Gag-Pol-Nef du virus de l'immunodéficience humaine (VIH-1) de sous-type B (MVA-B), sur lesquels le gène de vaccine C6L a connu une délétion, et qui sont conçus pour être utilisés comme vaccins contre le VIH/SIDA et d'autres maladies.
PCT/ES2012/070521 2011-07-19 2012-07-11 Vecteurs recombinants à base du virus ankara modifié (mva) avec délétion dans le gène c6l, utilisés comme vaccins contre le vih/sida et d'autres maladies WO2013011179A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201131230A ES2401904B1 (es) 2011-07-19 2011-07-19 Vectores recombinantes basados en el virus modificado de ankara (mva), con deleción en el gen c6l, como vacunas contra el vih/sida y otras enfermedades.
ESP201131230 2011-07-19

Publications (2)

Publication Number Publication Date
WO2013011179A2 WO2013011179A2 (fr) 2013-01-24
WO2013011179A3 true WO2013011179A3 (fr) 2013-03-14

Family

ID=47558548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2012/070521 WO2013011179A2 (fr) 2011-07-19 2012-07-11 Vecteurs recombinants à base du virus ankara modifié (mva) avec délétion dans le gène c6l, utilisés comme vaccins contre le vih/sida et d'autres maladies

Country Status (2)

Country Link
ES (1) ES2401904B1 (fr)
WO (1) WO2013011179A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086980A1 (fr) * 2014-12-02 2016-06-09 Consejo Superior De Investigaciones Cientificas Composition de vaccin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085932A2 (fr) * 2000-05-10 2001-11-15 Aventis Pasteur Limited Polypeptides immunogeniques codes par des minigenes mage et leurs utilisations
WO2010127115A1 (fr) * 2009-04-30 2010-11-04 Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) Vecteurs d'immunisation modifiés

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085932A2 (fr) * 2000-05-10 2001-11-15 Aventis Pasteur Limited Polypeptides immunogeniques codes par des minigenes mage et leurs utilisations
WO2010127115A1 (fr) * 2009-04-30 2010-11-04 Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) Vecteurs d'immunisation modifiés

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GARCIA-ARRIAZA, J ET AL.: "A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses", PLOS ONE, vol. 6, no. 8, August 2011 (2011-08-01) *
GARCIA-ARRIAZA, J ET AL.: "Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions", PLOS ONE, vol. 5, no. 8, August 2010 (2010-08-01) *
GONZALEZ, J. M ET AL.: "A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history", VIROLOGY JOURNAL, vol. 7, no. 1, March 2010 (2010-03-01) *
GUERRA, S ET AL.: "Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS", JOURNAL OF VIROLOGY, vol. 84, no. 16, August 2010 (2010-08-01), pages 8141 - 8152 *
UNTERHOLZNER, L ET AL.: "Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7.", PLOS PATHOGENS, vol. 7, no. 9, September 2011 (2011-09-01) *

Also Published As

Publication number Publication date
ES2401904B1 (es) 2014-04-07
WO2013011179A2 (fr) 2013-01-24
ES2401904A2 (es) 2013-04-25
ES2401904R1 (es) 2013-06-05

Similar Documents

Publication Publication Date Title
WO2016109792A8 (fr) Nouveaux vaccins multivalents à base de nanoparticules
HK1214509A1 (zh) 穏定的人類免疫缺陷病毒(hiv)包膜蛋白基因(env)三聚體疫苗及其使用方法
EP4043031A3 (fr) Constructions à base d'antigènes du virus zika
WO2016020856A3 (fr) Réactifs immunologiques
WO2007095318A3 (fr) antigenes de la grippe, compositions de vaccins et procedes associes
EP3266464A3 (fr) Thérapeutique à base de levure pour infection chronique par l'hépatite b
NZ702145A (en) Bluetongue virus recombinant vaccines and uses thereof
BR112013012555A2 (pt) peptídeos imunogênicos para o uso na prevenção e/ou no tratamento de doenças infecciosas, doenças autoimunes, respostas imunes a alofatores, doenças alérgicas, tumores, rejeição a enxertos e respostas imunes contra vetores virais usados para a terapia de genes ou na vacinação de genes
WO2010019262A3 (fr) Vaccin polyvalent
PH12013502322A1 (en) Hendra and nipah virus g glycoprotein immunogenic compositions
WO2007095320A3 (fr) Antigènes du papillomavirus humain, compositions de vaccin et méthodes
WO2014052378A3 (fr) Vaccins sous-unitaires par immersion pour les poissons
CA2860388C (fr) Vaccins bases sur le virus parainfluenza 5
WO2012106231A3 (fr) Vecteurs viraux recombinants et procédés d'induction d'une réponse immunitaire hétéro sous-typique aux virus de la grippe a
WO2015052543A3 (fr) Vaccination antipaludique
HK1207871A1 (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
MX346475B (es) Peptidos inmunogenicos monomericos y multimericos.
EP3971298A3 (fr) Compositions et méthodes permettant d'induire une réponse immunitaire améliorée au moyen des vecteurs de poxvirus
EP3939604A3 (fr) Vaccins contre la grippe à base de protéine hémagglutinine
EP4494651A3 (fr) Virus modifies
WO2011119716A3 (fr) Mutations de gamme d'hôtes du flavivirus et leurs utilisations
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
WO2012116253A3 (fr) Vaccin recombinant contre le virus des oreillons
WO2015123592A3 (fr) Particules d'arn recombiné et méthodes d'utilisation
WO2012003320A3 (fr) Mutations de gamme d'hôtes de flavivirus et leurs utilisations

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12815519

Country of ref document: EP

Kind code of ref document: A2